重症急性胰腺炎并发脓毒症患者血清HMGB1、IL-6及STAT3的表达水平与预后相关性研究

ISSN:2811-051X(P)

EISSN:2811-0781(O)

语言:中文

作者
曾文驰,陈鸣娣,董宏裕,江国栋,黎焯基
文章摘要
目的:探讨重症急性胰腺炎(SAP)并发脓毒症患者血清中高迁移率族蛋白B1(HMGB1)、白细胞介素-6(IL-6)及信号转导与转录激活因子3(STAT3)水平与临床预后的相关性。方法:前瞻性纳入2022年9月至2023年9月收治的84例SAP合并脓毒症患者,根据脓毒性休克诊断标准分为普通脓毒症组(58例)和脓毒症休克组(26例)。采用ELISA法检测两组患者入院24小时内血清HMGB1、IL-6及STAT3水平,比较组间差异并分析28天内病死率。结果:脓毒症休克组的血清HMGB1、IL-6 和STAT3水平分别为81.16±15.62 ng/mL、142.16±29.45 pg/mL、1.76±0.41 pg/mL,较普通组分别升高1.78、1.39和1.52倍(P<0.01)。脓毒症休克组患者28天内病死率为42.31%(11/26),显著高于普通组的20.69%(12/58)(χ²=5.307,P=0.011)。结论:HMGB1/IL-6/STAT3信号通路激活程度与SAP合并脓毒症患者的病情严重程度及不良预后显著相关,联合检测可能为早期识别高危患者提供生物标志物组合。
文章关键词
脓毒症;重症急性胰腺炎;高迁移率族蛋白B1;白细胞介素6;STAT3转录因子
参考文献
[1] Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA. 2016;315(8):801-810. [2] Hotchkiss RS, Moldawer LL, Opal SM, et al. Sepsis and septic shock. Nat Rev Dis Primers.2016;2:16045. [3] Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-251. [4] Kwak MS, Lim M, Lee YJ, et al. HMGB1 Binds to Lipoteichoic Acid and Enhances TNF-alpha and IL-6 Production through HMGB1-Mediated Transfer of Lipoteichoic Acid to CD14 and TLR2.J Innate Immun. 2015;7(4):405-416. [5] Hirano T.IL-6 in inflammation, autoimmunity and cancer.Int Immunol. 2021; 33(3):127-148. [6] 吴红雪,王厚清,燕宪亮,等.重症急性胰腺炎合并脓毒症与病原菌特征、凝血功能及微循环障碍的相关性研究[J].医学研究杂志,2022,51(03):108-112. [7] Forcina L, Franceschi C, Musarò A. The hormetic and hermetic role of IL-6. Ageing Res Rev. 2022;80:101697. [8] Kumar S, Aziz T, Kumar R, et al. Diagnostic accuracy of interleukin-6 as a biomarker for early prediction of severe acute pancreatitis: A systematic review and meta-analysis. J Family Med Prim Care. 2025;14(2):667-674. [9] Musharaf I, Nashwan AJ. Association of interleukin-6 with acute lung injury risk and disease severity in sepsis.World J Clin Cases. 2025;13(8):98379. [10] Li S, Lin J, Huang L, et al. STK31 drives tumor immune evasion through STAT3-IL-6 mediated CD8(+) T cell exhaustion. Oncogene. 2025. [11] Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234-248. [12] Yun BH, Kim S, Chon SJ, et al.High mobility group box-1 promotes inflammation in endometriotic stromal cells through Toll-like receptor 4/nuclear factor-kappa B. Am J Transl Res. 2021;13(3):1400-1410. [13] Bolay H, Karadas Ö, Oztürk B, et al. HMGB1, NLRP3, IL-6 and ACE2 levels are elevated in COVID-19 with headache: a window to the infection-related headache mechanism.J Headache Pain. 2021;22(1):94. [14] Gao H, Zhang X, Zheng Y, et al. S100A9-induced release of interleukin (IL)-6 and IL-8 through toll-like receptor 4 (TLR4) in human periodontal ligament cells.Mol Immunol. 2015;67(2):223-232. [15] Nativel B, Marimoutou M, Thon-Hon VG, et al. Soluble HMGB1 is a novel adipokine stimulating IL-6 secretion through RAGE receptor in SW872 preadipocyte cell line: contribution to chronic inflammation in fat tissue. PLoS One. 2013;8(9):e76039. [16] Wang B, Shu Y, Wang J, et al. Coptis chinensis Franch Relies on Berberine to Alleviate Stomach Heat Syndrome through the JAK2-STAT3-NF-κB Signaling Pathway and Amino Acid Metabolism Regulation. Curr Pharm Des. 2025. [17] Komar HM, Serpa G, Kerscher C, et al. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo.Sci Rep. 2017;7(1):1787.
Full Text:
DOI